The Importance of Having a Will It started with a 13-year melanoma survivor letting us know that he had put us in his will. Jeff Berg,…
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma By Kim Margolin, M.D., FACP, FASCO Background—Immunotherapy of melanoma The explosion of immunotherapy over the past decade has revolutionized the…
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Living Beyond Melanoma: A Conversation with Stage IV Melanoma Survivor, Stephanie Bowen In this episode, Melissa Wilson, PA-C, MPAS, AIM’s “Ask a Medical Expert” and host of the webinar series, “From the…
Diagnosed with Melanoma as a Teenager Changed My Life’s Course By Mara Klecker Madison Goff spent her early teenage years tanning in her family’s tanning bed or laying by the…
Create a Legacy with AIM October 17th – 23rd, 2022 is National Estate Planning Awareness Week Creating a legacy gift that supports melanoma research in…
Talking to Your Care Team about Your Sexual Orientation and Gender Identity While it may be an uncomfortable topic to bring up, sharing your sexual orientation and gender identity with your cancer…
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma (Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Val Guild Honored at 2022 ASCO Annual Conference by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
President’s Letter | September 2022 From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026 Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)